Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903).
Edmondson RJ, O'Connell RL, Banerjee S, Mileshkin L, Sykes P, Beale P, Fisher A, Bonaventura A, Millan D, Nottley S, Benson C, Hamilton A, Sjoquist K, Alexander L, Kelly C, Carty K, Divers L, Bradshaw N, Friedlander M; PARAGON investigators. Edmondson RJ, et al. Gynecol Oncol. 2021 Dec;163(3):524-530. doi: 10.1016/j.ygyno.2021.09.010. Epub 2021 Oct 5. Gynecol Oncol. 2021. PMID: 34625284 Clinical Trial.
Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial.
Stockler MR, O'Connell R, Nowak AK, Goldstein D, Turner J, Wilcken NR, Wyld D, Abdi EA, Glasgow A, Beale PJ, Jefford M, Dhillon H, Heritier S, Carter C, Hickie IB, Simes RJ; Zoloft's Effects on Symptoms and survival Time Trial Group. Stockler MR, et al. Lancet Oncol. 2007 Jul;8(7):603-12. doi: 10.1016/S1470-2045(07)70148-1. Lancet Oncol. 2007. PMID: 17548243 Clinical Trial.
Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum-resistant/refractory recurrent ovarian cancer: the gynecologic cancer intergroup symptom benefit study.
Sjoquist KM, Friedlander ML, O'Connell RL, Voysey M, King MT, Stockler MR, Oza AM, Gillies K, Martyn JK, Butow PN. Sjoquist KM, et al. Oncologist. 2013;18(11):1221-8. doi: 10.1634/theoncologist.2013-0175. Epub 2013 Oct 9. Oncologist. 2013. PMID: 24107972 Free PMC article.
Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study.
Friedlander ML, Stockler M, O'Connell R, Voysey M, Oza A, Gillies K, Donovan H, Martyn J, Sjoquist K, Butow P, King MT; Symptom Benefit Study Group. Friedlander ML, et al. Int J Gynecol Cancer. 2014 Jun;24(5):857-64. doi: 10.1097/IGC.0000000000000147. Int J Gynecol Cancer. 2014. PMID: 24844219
Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer.
King MT, Stockler MR, Butow P, O'Connell R, Voysey M, Oza AM, Gillies K, Donovan HS, Mercieca-Bebber R, Martyn J, Sjoquist K, Friedlander ML. King MT, et al. Int J Gynecol Cancer. 2014 Jun;24(5):865-73. doi: 10.1097/IGC.0000000000000167. Int J Gynecol Cancer. 2014. PMID: 24844220
TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer.
Ferraro D, Goldstein D, O'Connell RL, Zalcberg JR, Sjoquist KM, Tebbutt NC, Grimison P, McLachlan S, Lipton LL, Vasey P, Gebski VJ, Aiken C, Cronk M, Ng S, Karapetis CS, Shannon J; behalf of the the Australasian Gastro-Intestinal Trials Group. Ferraro D, et al. Cancer Chemother Pharmacol. 2016 Aug;78(2):361-7. doi: 10.1007/s00280-016-3089-4. Epub 2016 Jun 22. Cancer Chemother Pharmacol. 2016. PMID: 27335026 Clinical Trial.
Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial.
ANZGOG and PORTEC Group; Blinman P, Mileshkin L, Khaw P, Goss G, Johnson C, Capp A, Brooks S, Wain G, Kolodziej I, Veillard AS, O'Connell R, Creutzberg CL, Stockler MR. ANZGOG and PORTEC Group, et al. Br J Cancer. 2016 Nov 8;115(10):1179-1185. doi: 10.1038/bjc.2016.323. Epub 2016 Oct 20. Br J Cancer. 2016. PMID: 27764842 Free PMC article. Clinical Trial.
Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer.
Bonaventura A, OʼConnell RL, Mapagu C, Beale PJ, McNally OM, Mileshkin LR, Grant PT, Hadley AM, Goh JCH, Sjoquist KM, Martyn J, DeFazio A, Scurry J, Friedlander ML; Paragon Investigators. Bonaventura A, et al. Int J Gynecol Cancer. 2017 Jun;27(5):900-906. doi: 10.1097/IGC.0000000000000978. Int J Gynecol Cancer. 2017. PMID: 28498256 Clinical Trial.
Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
Roncolato FT, Berton-Rigaud D, O'Connell R, Lanceley A, Sehouli J, Buizen L, Okamoto A, Aotani E, Lorusso D, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Hilpert F, Ledermann JA, Kaminsky MC, Stockler MR, King MT, Friedlander M. Roncolato FT, et al. Gynecol Oncol. 2018 Jan;148(1):36-41. doi: 10.1016/j.ygyno.2017.10.019. Epub 2017 Oct 26. Gynecol Oncol. 2018. PMID: 29107348 Free article.
159 results